Metraipolis › archive › dc_1674aecaa279
Viloxazine — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Viloxazine
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-07T18:35:16.990Z
- SHA-256 of the archived text
ede096f769d4b1515f099ef39cf6b3cf532e7ea5e8cafdf31783226cd68e0aaf- Stable URL of this page
https://metraipolis.com/documento/dc_1674aecaa279
How to cite
Viloxazine — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Viloxazine (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_1674aecaa279 (Metraipolis archive dc_1674aecaa279, sha256 ede096f769d4b1515f099ef39cf6b3cf532e7ea5e8cafdf31783226cd68e0aaf)
BibTeX
@misc{dc1674aecaa279,
title = {Viloxazine — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Viloxazine},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_1674aecaa279; sha256 ede096f769d4b1515f099ef39cf6b3cf532e7ea5e8cafdf31783226cd68e0aaf},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Viloxazine. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication that is indicated in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form, although current evidence indicates that it is significantly less effective at reducing ADHD symptoms compared to stimulant medications like methylphenidate. Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure. Rarely, the medication may cause suicidal thoughts and behaviors. It can also activate mania or hypomania in people with bipolar disorder. Viloxazine acts as a selective norepinephrine reuptake inhibitor (sNRI). The immediate-release form has an elimination half-life of 2.5 hours while the half-life of the extended-release form is 7 hours. Viloxazine was first described by 1972 and was marketed as an antidepressant in Europe in 1974. It was not marketed in the United States at this time. The medication was discontinued in 2002 for commercial reasons. However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021. Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance. Tema degli esploratori: scienze della vita e salute (deposito sistematico; ricerca «pharmacology»). Fonte: Wikipedia in inglese, voce «Viloxazine» — https://en.wikipedia.org/wiki/Viloxazine Wikidata Q907148: «group of stereoisomers» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q907148 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Viloxazine?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1383609717, consultata il 2026-11-07T18:31:02.251Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 1ca5198b86502dced1bf6ac043f1e322de45167a48f6cc5540d726eed2b2829e